Antibody-drug conjugate(ADC),a new type of targeted drugs for breast cancer,is formed by connecting a chemotherapeutic drug with a monoclonal antibody using a linker.The monoclonal antibody is used as a carrier to transport the chemotherapeutic drug to the specific tumor cells,thereby exerting anti-tumor effects.ADCs are classified into human epidermal growth factor receptor 2(HER2),human trophoblast surface antigen 2(Trop-2),and other molecules according to antigens that act on the different target.At present,there are three ADCs approved worldwide for the treatment of breast cancer.In addition to trastuzumab emtansine(T-DM1)and trastuzumab deruxtecan(T-DXd)for HER2-positive breast cancer,sacituzumab govitecan(SG)is beneficial for triple-negative breast cancer(TNBC).ADCs are effective in the treatment of HER2-positive breast cancer,and also have made important progress in the treatment of advanced TNBC and some HER2 low-expressing breast cancer.These ADCs provide more options for patients with different molecular types of breast cancer.
关键词
乳腺肿瘤/受体,erbB-2/临床研究/抗体偶联药物
Key words
breast neoplasms/receptor,erbB-2/clinical study/antibody-drug conjugate
维普
万方数据